<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02070289</url>
  </required_header>
  <id_info>
    <org_study_id>B7431002</org_study_id>
    <nct_id>NCT02070289</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06372865 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)</brief_title>
  <official_title>A Phase 1 Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of Pf-06372865 In Subjects Aged 18-55 (Group 1) And 56-75 Years (Group 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate safety, toleration and time course of plasma
      concentration of multiple oral doses of PF-06372865 for 14 days in healthy subjects of two
      age groups, 18-55 years (Group 1) and 56-75 years (Group 2).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau)</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1: Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 or 2: Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 or 2: Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06372865</intervention_name>
    <description>Tablets, 2.5 mg BID, 14 days</description>
    <arm_group_label>Group 1: Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, BID, 14 days</description>
    <arm_group_label>Group 1: Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06372865</intervention_name>
    <description>Tablets, to be decided dose, BID or titration, 14 days</description>
    <arm_group_label>Group 1: Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, BID or titration, 14 days</description>
    <arm_group_label>Group 1: Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06372865</intervention_name>
    <description>Tablets, to be decided dose, BID or titration, 14 days</description>
    <arm_group_label>Group 1: Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, BID or titration, 14 days</description>
    <arm_group_label>Group 1: Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06372865</intervention_name>
    <description>Tablets, to be decided dose, BID or titration, 14 days</description>
    <arm_group_label>Group 2: Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, BID or titration, 14 days</description>
    <arm_group_label>Group 2: Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06372865</intervention_name>
    <description>Tablets, to be decided dose, BID or titration, 14 days</description>
    <arm_group_label>Group 1 or 2: Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, BID or titration, 14 days</description>
    <arm_group_label>Group 1 or 2: Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06372865</intervention_name>
    <description>Tablets, to be decided dose, BID or titration, 14 days</description>
    <arm_group_label>Group 1 or 2: Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Group 1 specific: Healthy male and/or female subjects of non-childbearing
             potential between the ages of 18 and 55 years, inclusive at Screening. Healthy is
             defined as no clinically relevant abnormalities identified by a detailed medical
             history, full physical examination, including blood pressure and pulse rate
             measurement, 12-lead ECG and clinical laboratory.

          -  For Group 2 specific: Male and/or female subjects of non-childbearing potential
             between the ages of 56 and 75 years, inclusive at Screening. Subjects must be in
             reasonably good health as determined by the Investigator based on a detailed medical
             history, full physical examination (including blood pressure and pulse rate
             measurement), 12-lead ECG and clinical laboratory tests. Subjects with mild, chronic,
             stable disease (eg, osteoarthritis) may be enrolled if deemed medically prudent by the
             Investigator. At least 50% of the subjects enrolled in these cohorts must be 60 years
             of age and above at Screening.

          -  For Group 2 specific: Subjects taking daily prescription or non-prescription
             medications for management of acceptable chronic medical conditions must be on a
             stable dose of these, as defined by non change in dose for the 3 months prior to the
             first dose of study medication and no planned changes during the conduct of the study.

        Exclusion Criteria:

          -  For Group 1 specific: Evidence or history of clinically significant hematological,
             renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric,
             neurologic, or allergic disease (including drug allergies, but excluding untreated,
             asymptomatic, seasonal allergies at time of dosing).

          -  For Group 2 specific : Evidence or history of unstable disease or moderate to severe
             conditions which would, in the Investigator's opinion, interfere with the study
             evaluations or impact on the safety of participating subjects, such as orthostatic
             hypotension.

          -  Subjects with history of sleep apnea

          -  Any condition possibly affecting drug absorption (eg, gastrectomy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7431002&amp;StudyName=A%20Study%20to%20Evaluate%20Safety%2C%20Toleration%20and%20Time%20Course%20of%20Plasma%20Concentration%20of%20Multiple%20Oral%20Doses%20of%20PF-06372865%20in%20Healthy%20Subj</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2014</study_first_submitted>
  <study_first_submitted_qc>February 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <last_update_submitted>August 15, 2014</last_update_submitted>
  <last_update_submitted_qc>August 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple dose</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>PK</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

